Noninvasive blood test tracks organ injury from COVID-19

Cornell University
29-Jan-2021 10:15 AM EST, by Cornell University

Newswise — ITHACA, N.Y. – Surgical biopsy can be crucial to tracking the damage of disease and infection in the body, but the procedure can take its own toll on the patient.

A Cornell-led collaboration has developed a noninvasive blood test that uses cell-free DNA to gauge the damage that COVID-19 inflicts on cells, tissues and organs, and could help aid in the development of new therapies.

The team’s paper, “Cell-Free DNA Tissues-of-Origin by Methylation Profiling Reveals Significant Cell, Tissue and Organ-Specific Injury Related to COVID-19 Severity,” published Jan. 16 in Cell Med. The co-lead authors are doctoral student Alex Cheng; Dr. Matthew Pellan Cheng, assistant professor of medicine atMcGill University Health Center; and Wei Gu, assistant professor of pathology at Stanford University.

“A lot of what we’ve learned about the involvement of the virus with different organs is from invasive biopsies, postmortem biopsies,” said corresponding author Iwijn De Vlaminck, an assistant professor in the Meinig School of Biomedical Engineering. “But a liquid biopsy is potentially very useful as a biological measurement, a way to study what is going on in patients who have different types of symptoms, for example.

“It could be used to assess disease severity and help stratify patients in the care system,” De Vlaminck said. “It could also potentially be a surrogate biomarker that you could include in randomized controlled trials of various anti-COVID therapies and anti-virals.”

For several years, De Vlaminck and Cheng have been exploring the biomedical applications of cell-free DNA – dead fragments of DNA that drift around the bloodstream and urine. The fragments are relatively easy to collect via the body’s plasma. By profiling the DNA molecules and logging the occurrence of methylation marks – a chemical modification that results from the expression of different genes – the researchers can follow the fragments, much like trail of breadcrumbs, back to the source of injury or infection.

In 2019, they developed a test that used the technique to identify the presence of urinary tract infections in kidney transplant patients while also quantifying the degree of damage to the kidney and bladder.

As the COVID-19 pandemic emerged, the researchers realized their test could help search out and quantify the impact of COVID-19 on patients’ lungs and other organs and tissues.

Working with partners at McGill University and the Dana-Farber Cancer Institute, the researchers profiled 104 plasma samples from 33 COVID-19 patients, then compared the results with patients who had other viral infections, as well as healthy controls.

As expected, they found evidence of injury to the lungs, as well as the liver. More surprisingly, they noted an increase in DNA from red blood cell progenitors and found that a high concentration of cell-free DNA in the blood was itself a strong prognostic marker for severe COVID-19 cases.

“The total concentration of the free DNA in blood is something that can be measured pretty quickly,” De Vlaminck said. “If you’re not interested in figuring out where it’s coming from, or using complex genomic assays, it’s potentially useful for preclinical diagnostic workflows and workups because it can be integrated fairly easily.”

While liquid biopsies are often utilized in connection with cancer, they remain understudied in other diseases, Cheng said.

“When there’s a new virus that emerges, it’s not always clear what to look for,” Cheng said. “Clinicians are looking for specific injury to the kidney or to the liver or the lungs. I think that an unsupervised assay like ours during a pandemic setting, when we don’t really know much about what’s going on, is important because it’ll tell us where we can start to look for more information.”

Co-authors include Cornell researcher Joan Sesing Lenz; and researchers from McGill University, University of California, San Francisco, and Dana-Farber Cancer Institute.

The research was supported by the National Institutes of Health, the Rainin Foundation, a National Sciences and Engineering Research Council of Canada fellowship, the Burroughs-Wellcome Fund, and a SARS-CoV-2 seed grant from Cornell’s Office of the Vice President for Research and Innovation.


Filters close

Showing results

110 of 5625
Released: 12-May-2021 5:10 PM EDT
Understanding SARS-COV-2 proteins is key to improve therapeutic options for COVID-19
Bentham Science Publishers

COVID-19 has had a significant impact since the pandemic was declared by WHO in 2020, with over 3 million deaths and counting, Researchers and medical teams have been hard at work at developing strategies to control the spread of the infection, caused by SARS-COV-2 virus and treat affected patients.

Newswise: 264700_web.jpg
Released: 12-May-2021 4:55 PM EDT
COVID-19 vaccine does not damage the placenta in pregnancy
Northwestern University

A new Northwestern Medicine study of placentas from patients who received the COVID-19 vaccine during pregnancy found no evidence of injury, adding to the growing literature that COVID-19 vaccines are safe in pregnancy.

Released: 12-May-2021 3:45 PM EDT
Parks not only safe, but essential during the pandemic
Drexel University

Parks played an important role for people seeking respite from the toll of social isolation during the pandemic, and according to new research from Drexel University, they did so without increasing the spread of COVID-19.

access_time Embargo lifts in 2 days
Embargo will expire: 18-May-2021 11:00 AM EDT Released to reporters: 12-May-2021 3:35 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 18-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Pandemic Has 'Severely Weakened Surgical Innovation Pipeline'
Released: 12-May-2021 3:15 PM EDT
Pandemic Has 'Severely Weakened Surgical Innovation Pipeline'
Johns Hopkins University Carey Business School

In a new study for the journal Surgical Innovation, Associate Professor Toby Gordon of the Johns Hopkins Carey Business School addresses the ways in which COVID-19 has slowed medical innovation.

Released: 12-May-2021 2:55 PM EDT
Mental health helplines need human-centered solutions
Cornell University

In India today, dozens of phone numbers are available for people who are having a severe mental health emergency. Oftentimes, however, callers experience difficulty in getting connected with someone who will listen to them; sometimes the phone will just ring and ring.

Newswise: Weizmann Institute Scientists Reveal the Triple Threat of Coronavirus
Released: 12-May-2021 2:40 PM EDT
Weizmann Institute Scientists Reveal the Triple Threat of Coronavirus
Weizmann Institute of Science

Scientists at the Weizmann Institute and the Israel Institute for Biological, Chemical and Environmental Sciences took a novel tack to investigating SARS-CoV-2’s powerful ability to infect, finding that the virus deploys an apparently unique three-pronged strategy to take over the cell’s protein-synthesis abilities. The work could help develop effective Covid-19 treatments.

Newswise: Rush Collaborates With Malcolm X College to Train COVID-19 Vaccine Ambassadors
Released: 12-May-2021 2:20 PM EDT
Rush Collaborates With Malcolm X College to Train COVID-19 Vaccine Ambassadors
Rush University Medical Center

Rush staff members collaborated with Malcom X College to provide content including video scenarios and conversation advice, for a new Vaccine Ambassador Course offered to the public.

Newswise: Using Ultrasound Stimulation to Reduce Inflammation in COVID-19 In-Patients
Released: 12-May-2021 1:35 PM EDT
Using Ultrasound Stimulation to Reduce Inflammation in COVID-19 In-Patients
University of California San Diego Health

Researchers at UC San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays.

Released: 12-May-2021 9:00 AM EDT
Rapid COVID-19 Diagnostic Test Delivers Results Within 4 Minutes With 90 Percent Accuracy
Perelman School of Medicine at the University of Pennsylvania

A low-cost, rapid diagnostic test for COVID-19 developed by Penn Medicine provides COVID-19 results within four minutes with 90 percent accuracy. A paper published this week in Matter details the fast and inexpensive diagnostic test, called RAPID 1.0. Compared to existing methods for COVID-19 detection, RAPID is inexpensive and highly scalable, allowing the production of millions of units per week.

Showing results

110 of 5625